Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

The Company’s pipeline includes programs focused on chronic wounds, degenerative diseases, immunology, and regenerative medicine. Applied Biologics is committed to advancing innovative biologic ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled ...

Early initiation of biologic therapy in patients with Crohn’s disease (CD) is associated with higher rates of transmural healing and leads to improved long-term outcomes. In CD, early initiation of ...

In parallel, Applied Biologics continues to advance a broader pipeline of biologic therapies and technologies across chronic wounds, tissue repair, and degenerative disease, including translational ...

Panelists discuss how biologic therapy selection depends on disease burden rather than just body surface area (BSA), with monitoring requiring objective measures, patient-reported outcomes, and ...

Earlier initiation of biologics in severe asthma could prevent thousands of deaths and save billions in healthcare costs by reducing exacerbations and healthcare resource utilization. Real-world data ...

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

A clinical trial co-led by the Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug certolizumab significantly reduces the risk of serious adverse pregnancy outcomes ...

For patients with moderate to severe eosinophilic asthma or oral corticosteroid (OCS)-dependent asthma and inadequate disease control, the decision to add biologic therapy is based on the patient’s ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We are really fortunate to be managing ...

U.S. Biobetters Market to Hit USD 54.94 Billion and Europe Market to Reach USD 37.29 Billion by 2035, Driven by Biologics Patent Expirations and Therapeutic Innovation.Austin, United States, June 11, ...